Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of TPV/r Oral Solution vs Capsules
NCT02227017Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2006
- Primary completion
- Apr 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve of TPV from time zero to 12 hours at steady state. Started Feb 2006; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02227017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227017.